We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cancer Space Update: Pfizer's Bavencio Fails in Phase III
Read MoreHide Full Article
There was no major news in the cancer space this week, except the failure of Pfizer Inc.’s (PFE - Free Report) Bavencio in a gastric cancer study. In a setback to Eisai Co., Ltd. , National Institute of Health and Care Excellence (“NICE”) did not recommend the approval of its breast cancer drug, Halaven, for use in second-line setting in UK.
Meanwhile, AstraZeneca’s (AZN - Free Report) filing for label expansion of Tagrisso in first-line setting for treating lung cancer was accepted by the European Medicines Agency (“EMA”). Apart from this, Bristol-Myers’ (BMY - Free Report) blockbuster drug, Opdivo, again proved its worth by achieving superior overall survival (“OS”) in a phase III lung cancer study. Moreover, Celldex Therapeutics, Inc. (CLDX - Free Report) also announced initiation of a phase I study on its new oncology candidate, CDX-1140, in solid tumors.
Recap of the Week’s Most Important Stories
Pfizer’s Bavencio Fails in Gastric Cancer Study: Pfizer along with its Germany-based partner Merck KGaA announced the failure of a phase III study evaluating their key pipeline candidate, Bavencio (avelumab), for the treatment of gastric cancer in third-line setting.
The study – JAVELIN Gastric 300 – evaluated Bavencio as a monotherapy in patients with unresectable, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma and whose disease has progressed following two prior therapeutic regimens. However, another study, JAVELIN Gastric 100, continues to evaluate the drug in first-line switch maintenance setting. (Read more: Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study)
Eisai’s Halaven Suffers Setback in UK: Eisai announced that NICE did not recommend approval for Halaven in UK in second-line setting for treating locally advanced or metastatic breast cancer who have received chemotherapy. The approval would have given competitive advantage to the drug. The drug is already approved in the UK in third or later line setting for the same indication.
Bristol-Myers’ Opdivo Superior in Lung Cancer Study: Bristol-Myers’ PD-1 immune checkpoint inhibitor, Opdivo, achieved superior OS compared to docetaxel in a phase III study. The study – CheckMate -078 – evaluated the drug in previously treated advanced or metastatic non-small cell lung cancer. The study, which was conducted mainly in Chinese patients, achieved its primary endpoint of OS earlier than expected. The company’s biologics license application, filed on the basis of the positive results from the study, has been accepted by the China Food and Drug Administration.
This week the EMA accepted Mylan’s marketing authorization applications for a biosimilar of Roche’s (RHHBY - Free Report) breast and gastric cancer drug, Herceptin, and Amgen’s neutropenia drug, Neulasta.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Cancer Space Update: Pfizer's Bavencio Fails in Phase III
There was no major news in the cancer space this week, except the failure of Pfizer Inc.’s (PFE - Free Report) Bavencio in a gastric cancer study. In a setback to Eisai Co., Ltd. , National Institute of Health and Care Excellence (“NICE”) did not recommend the approval of its breast cancer drug, Halaven, for use in second-line setting in UK.
Meanwhile, AstraZeneca’s (AZN - Free Report) filing for label expansion of Tagrisso in first-line setting for treating lung cancer was accepted by the European Medicines Agency (“EMA”). Apart from this, Bristol-Myers’ (BMY - Free Report) blockbuster drug, Opdivo, again proved its worth by achieving superior overall survival (“OS”) in a phase III lung cancer study. Moreover, Celldex Therapeutics, Inc. (CLDX - Free Report) also announced initiation of a phase I study on its new oncology candidate, CDX-1140, in solid tumors.
Recap of the Week’s Most Important Stories
Pfizer’s Bavencio Fails in Gastric Cancer Study: Pfizer along with its Germany-based partner Merck KGaA announced the failure of a phase III study evaluating their key pipeline candidate, Bavencio (avelumab), for the treatment of gastric cancer in third-line setting.
The study – JAVELIN Gastric 300 – evaluated Bavencio as a monotherapy in patients with unresectable, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma and whose disease has progressed following two prior therapeutic regimens. However, another study, JAVELIN Gastric 100, continues to evaluate the drug in first-line switch maintenance setting. (Read more: Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study)
Pfizer, Inc. Price
Pfizer, Inc. Price | Pfizer, Inc. Quote
Eisai’s Halaven Suffers Setback in UK: Eisai announced that NICE did not recommend approval for Halaven in UK in second-line setting for treating locally advanced or metastatic breast cancer who have received chemotherapy. The approval would have given competitive advantage to the drug. The drug is already approved in the UK in third or later line setting for the same indication.
Eisai Co. Price
Eisai Co. Price | Eisai Co. Quote
Bristol-Myers’ Opdivo Superior in Lung Cancer Study: Bristol-Myers’ PD-1 immune checkpoint inhibitor, Opdivo, achieved superior OS compared to docetaxel in a phase III study. The study – CheckMate -078 – evaluated the drug in previously treated advanced or metastatic non-small cell lung cancer. The study, which was conducted mainly in Chinese patients, achieved its primary endpoint of OS earlier than expected. The company’s biologics license application, filed on the basis of the positive results from the study, has been accepted by the China Food and Drug Administration.
Bristol-Myers Squibb Company Price
Bristol-Myers Squibb Company Price | Bristol-Myers Squibb Company Quote
This week the EMA accepted Mylan’s marketing authorization applications for a biosimilar of Roche’s (RHHBY - Free Report) breast and gastric cancer drug, Herceptin, and Amgen’s neutropenia drug, Neulasta.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>